Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
Deepak L. Bhatt, MD, FACC*,*,
Marcus D. Flather, MD ,
Werner Hacke, MD ,
Peter B. Berger, MD, FACC ,
Henry R. Black, MD||,
William E. Boden, MD, FACC¶,
Patrice Cacoub, MD#,
Eric A. Cohen, MD**,
Mark A. Creager, MD, FACC,
J. Donald Easton, MD,
Christian W. Hamm, MD, FACC,
Graeme J. Hankey, MD||||,
S. Claiborne Johnston, MD, PhD¶¶,
Koon-Hou Mak, MD, FACC##,
Jean-Louis Mas, MD***,
Gilles Montalescot, MD, PhD,
Thomas A. Pearson, MD, FACC,
P. Gabriel Steg, MD, FACC,
Steven R. Steinhubl, MD, FACC||||||,
Michael A. Weber, MD, FACC¶¶¶,
Liz Fabry-Ribaudo, MSN, RN*,
Tingfei Hu, MS*,
Eric J. Topol, MD, FACC###,
Keith A.A. Fox, MBChB**** for the CHARISMA Investigators
* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom
Department of Neurology, University of Heidelberg, Heidelberg, Germany
Geisinger Center for Health Research, Danville, Pennsylvania
|| New York University School of Medicine, New York, New York
¶ Division of Cardiology, Kaleida Healthcare, Buffalo, New York
# Department of Internal Medicine, Hopital Pitie-Salpetriere, Paris, France
** Division of Cardiology, Sunnybrook and Women’s College Health Science Centre, Toronto, Canada
Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Department of Neurology, Rhode Island Hospital and Brown University, Providence, Rhode Island
Department of Cardiology, Kerckhoff-Klinik Center, Bad Nauheim, Germany
|||| Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia
¶¶ Department of Neurology, University of California San Francisco, San Francisco, California
## Gleneagles Medical Centre, Singapore
*** Department of Neurology and Stroke Unit, Sainte-Anne Hospital, Paris, France
Institut de Cardiologie — Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
Department of Community & Preventive Medicine, University of Rochester School of Medicine, Rochester, New York
Service de Cardiologie, Hôpital Bichat, Paris, France
|||||| Division of Cardiology, University of Kentucky, Lexington, Kentucky
¶¶¶ SUNY Downstate Medical Center College of Medicine, Brooklyn, New York
### Case Western Reserve University, Cleveland, Ohio
**** University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves for Cardiovascular Death, MI, or Stroke for Clopidogrel + ASA Versus Placebo + ASA
Kaplan-Meier event curves for the primary end point of cardiovascular death, myocardial infarction (MI), or stroke. ASA = aspirin; CI = confidence interval; RRR = relative risk reduction.
|
|
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Hazard Ratio for the Primary End Point in Patients Enrolled With Prior MI, Stroke, or PAD
Hazard ratio (HR) and 95% CI for the composite of cardiovascular death, MI, or stroke for patients randomized to placebo plus aspirin versus clopidogrel plus aspirin that were enrolled with a prior MI, prior ischemic stroke (IS), or symptomatic peripheral arterial disease (PAD). Abbreviations as in Figure 1.
|
|
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Curves for the Primary End Point in Patients With CAD Either With or Without Prior MI
(A) Kaplan-Meier curves for the primary end point of cardiovascular death, MI, or stroke in patients enrolled with prior MI. (B) Kaplan-Meier curves for the primary end point in patients enrolled with coronary artery disease without prior MI. Abbreviations as in Figures 1 and 2.
|
|
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Instantaneous Hazard for Cardiovascular Death, MI, or Stroke or for Severe or Moderate Bleeding
(A) Instantaneous hazard for cardiovascular death, MI, or stroke. (B) Instantaneous hazard for severe or moderate bleeding. Abbreviations as in Figure 1.
|
|
|
